|
|
Article: SHIRE PLC - Shire Announces NDA Submission Guanfacine for ADHD.
- Article from:
- PR Newswire UK Disclose
- Article date:
- August 24, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SHIRE ANNOUNCES NDA SUBMISSION OF GUANFACINE EXTENDED-RELEASE FOR THE TREATMENT
OF ADHD IN CHILDREN AND ADOLESCENTS
Shire Seeks FDA Approval of First Selective Alpha-2A-Adrenoceptor Agonist ADHD
Treatment, Which, if Approved, Broadens the ADHD Portfolio for Shire
Basingstoke, UK and Philadelphia, US - August 24, 2006 - Shire plc (LSE: SHP,
NASDAQ: SHPGY, TSX: SHQ) announced today that it has submitted a new drug
application (NDA) to the U.S. Food and Drug Administration (FDA) for its
investigational compound guanfacine extended release (previously referred to as
SPD503), which, if approved, would be the first once-daily selective
alpha-2A-adrenoceptor agonist for the ...